All In Biotech

Drug Trial Radar · NCT05304377

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

May 22, 2022

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Enliven TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.

Conditions

  • Chronic Myeloid Leukemia
  • Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Cml

Interventions

  • ELVN-001Drug

    orally once or twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Incidence of dose limiting toxicitiesTime frame: 28 days
  2. Phase 1a: Incidence of adverse events (AEs)Time frame: up to 28 days
  3. Phase 1a: Incidence of clinically significant laboratory abnormalitiesTime frame: up to 28 days
  4. Phase 1a: Incidence of clinically significant ECG abnormalitiesTime frame: up to 28 days
  5. Phase 1b: Incidence of adverse eventsTime frame: up to 3 years
  6. Phase 1b: Incidence of clinically significant laboratory abnormalitiesTime frame: up to 3 years
  7. Phase 1b: Incidence of clinically significant ECG abnormalitiesTime frame: up to 3 years

Locations

45 sites in 14 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Oregon Health & Science University-Knight Cardiovascular Institute

    Portland, Oregon · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Royal Adelaide Hospital

    Adelaide, Australia · Recruiting

  • UZ Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • CHU Liege

    Liège, Belgium · Recruiting

  • University Health Network (UHN) - Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • CHU Amiens Picardie Site Sud

    Amiens, France · Recruiting

  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, France · Recruiting

  • CHRU de Lille - Hopital Calmette-Boulevard du Pr Leclercq CHRU Lille

    Lille, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) De Limoges Hopital Dupuytren

    Limoges, France · Terminated

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France · Withdrawn

  • Uniklinik RWTH Aachen Medizinische

    Aachen, Germany · Recruiting

  • Charite Campus Virchow

    Berlin, Germany · Recruiting

  • Klinikum der Goethe Universitat

    Frankfurt, Germany · Recruiting

  • Universitaetsklinikum Des Saarlandes Und Medizinische Fakultaet Der Universitaet Des Saarlandes

    Homburg, Germany · Recruiting

  • Universitaetsklinikum Jena

    Jena, Germany · Recruiting

  • Medizinische Universitatsklinik Mannheim der Universitat Heidelberg

    Mannheim, Germany · Recruiting

  • Universitaetsmedizin Rostock

    Rostock, Germany · Recruiting

  • Semmelweis Egyetem, Belgyogyaszati es Onkologiai Klinika

    Budapest, Hungary · Recruiting

  • Pecsi Tudomanyegyetem Klinikai Kozpont (University of Pecs, Clinical Centre)

    Pécs, Hungary · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • The Galilee Medical Center

    Nahariya, Israel · Recruiting

  • Rabin Medical Center

    Petah Tikva, Israel · Recruiting

  • Azienda Ospedaliero Universitaria Delle Marche

    Ancona, Italy · Recruiting

  • Radboud University Medical Center

    Nijmegen, Netherlands · Recruiting

  • Szpital Specjalistycnzy im. Jedrzeja Sniadeckiego w Nowym Saczu

    Nowy Sącz, Poland · Recruiting

  • MICS Centrum Medyczne Torun

    Torun, Poland · Recruiting

  • Instytut Hematologii I Transfuzjologii

    Warsaw, Poland · Recruiting

  • Keimyung University Dongsan Hospital

    Daegu, South Korea · Withdrawn

  • Uijeongbu Eulji Medical Center

    Gyeonggi-do, South Korea · Recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun, South Korea · Withdrawn

  • Samsung Medical Center

    Seoul, South Korea · Withdrawn

  • Chonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea · Withdrawn

  • Hospital Del Mar

    Barcelona, Spain · Recruiting

  • Hospital Universitario de Gran Canaria Dr. Negrin, Servicio Canario e Salud (SCS)

    Las Palmas de Gran Canaria, Spain · Withdrawn

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.